Isomorphic Labs Raises $600M for AI Drug Discovery

Isomorphic Labs, a London-based biotech firm and spinout from Google DeepMind, has raised $600 million in its first external funding round, led by Thrive Capital with participation from Alphabet and Google Ventures. Founded in 2021 by Sir Demis Hassabis, the company aims to revolutionize drug discovery using AI technology, including its Nobel Prize-winning model AlphaFold 3. The funding will be used to enhance its AI drug design engine and advance its clinical programs, with plans to have AI-designed drugs in trials by the end of 2025. Isomorphic has already secured partnerships with major pharmaceutical companies Eli Lilly and Novartis, worth nearly $3 billion combined, signaling strong investor confidence in its capabilities. Analysts view Isomorphic as a significant player in the AI biotech sector, indicating robust interest in AI-driven solutions for drug discovery. The substantial investment reflects the growing trend of integrating AI into various industries, particularly in pharmaceuticals.